Approval · Notice of Compliance 16888 · 2015
FETZIMA: Notice of Compliance 16888
Issued May 8, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16888
- Date
- May 8, 2015
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antidepressant
Products in this notice
Medicinal ingredients
- LEVOMILNACIPRAN 20 MG per CAP
- LEVOMILNACIPRAN 40 MG per CAP
- LEVOMILNACIPRAN 80 MG per CAP
- LEVOMILNACIPRAN 120 MG per CAP